1) **Welcome and Rollcall**

   I. **Welcome:**

      Meeting opened by Sharisse Kemp, ADAP Branch Chief

   II. **Introductions:**

      MAC Members, CDPH and Magellan introduced themselves

      **MAC Members in Attendance**
      Stephen O’Brien, Michelle Sherman, Danny Toub, Lucas Hill, David Grelotti, Laveeza Bhatti, David Lewis, Cliff Okada, Joanna Eveland, Glenn San Agustin

      **MAC Members not in Attendance**
      Wilbert Jordan, Laveeza Bhatti

      **CDPH/Office of AIDS staff in Attendance**
      Philip Peters, Sharisse Kemp, Becca Parks, James Vo, Alejandro Contreras, Glorietta Kundeti

      **Magellan Representatives in Attendance**
      Carrie Holden

2) **ADAP / MAC Updates**

   I. Medications added to the ADAP formulary:

      - Primaquine, rifapentine (priftin®), and rifaximin (xifaxan®) was added to the ADAP formulary.
      - Management Memorandum 2022-13 released on the expanded indication for recombinant zoster vaccine (Shingrix) in people with HIV aged 18 and older.
      - ADAP and PrEP-AP formularies was updated to remove Menactra and added MenQuadfi Meningococcal Conjugate Vaccine. Sanofi will be transitioning to MenQuadfi as their sole Meningococcal Conjugate Vaccine. A management memo will be released with further information on this update.
      - Ethinyl estradiol and norethindrone contraceptive medications was added to the ADAP formulary. Management Memorandum 2022-16 released on Oct. 12, 2022.
      - Lisinopril, benazepril, chlorthalidone, furosemide (Lasix®), hydrochlorothiazide (HCTZ), lisinopril plus HCTZ (Zestoretic®), losartan (Cozaar®) and losartan plus HCTZ (Hyzaar®) was added to the ADAP formulary. A management memo will be released with further information on this update.
      - Vaxneuvance (PCV15), Prevnar 20 (PCV20) and new HBV vaccine (PreHevbro) was added to the ADAP formulary.
      - Apretude, diabetes and STI treatment medications is currently under the cost analysis process, and it is being reviewed to make sure the cost would not impose a significant burden on program.
      - Monkeypox vaccine statement to be posted on CDPH website.
II. Medications removed from the ADAP formulary
   - None

III. Update on the medications discussed during the July’s 2022 MAC gathering:
   - Diabetes medications are currently under the cost analysis process.

3) **Medication Discussion**
   I. No new ARVs have received FDA approval

II. No public comments received

4) **PrEP-AP Formulary**
   I. Lucas Hill discussion on:
      - Medication-assisted treatment related to the PrEP-AP formulary.
        - Naltrexone
        - Buprenorphine

5) **Opportunistic Infection Treatments**
   I. No new opportunistic infection discussion

6) **Magellan Rx Presentation**
   I. Carrie Holden presented on:
      - Long-Acting Injectable Antipsychotics

7) **Close of Meeting**
   I. The next ADAP MAC gathering is scheduled for January 18, 2023, from 7:30 a.m. to 9:00 a.m.

8) **Action Items**

<table>
<thead>
<tr>
<th>Action Items</th>
<th>Owners</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review fentanyl test strips for the ADAP formulary</td>
<td>James Vo</td>
</tr>
<tr>
<td>Action Items</td>
<td>Owners</td>
</tr>
<tr>
<td>-------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>Injectable Naltrexone to the PrEP-AP formulary</td>
<td>James Vo</td>
</tr>
<tr>
<td>COVID Therapeutic to commercial use</td>
<td>Dr. Peters</td>
</tr>
</tbody>
</table>